Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guohong Han

Showing results (141-150 of 200) with videos related to

Pageof 20
Sort By:
BMC Cancer|December 24, 2017
Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II studyRuihua Xu, Xianjun Yu, Jihui Hao, et al.
BMJ Open|July 13, 2013
Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trialXingshun Qi, Chuangye He, Zhanxin Yin, et al.
Scientific Reports|February 3, 2016
The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial ChemoembolizationLei Liu, Yan Zhao, Jia Jia, et al.
Hepatology (Baltimore, Md.)|March 10, 2022
Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trialYong Lv, Hui Chen, Bohan Luo, et al.
The FEBS Journal|January 16, 2009
Inhibition of PI3K/Akt partially leads to the inhibition of PrP(C)-induced drug resistance in gastric cancer cellsJie Liang, Fulin Ge, Changcun Guo, et al.
The Lancet. Gastroenterology & Hepatology|May 19, 2022
Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trialYong Lv, Hui Chen, Bohan Luo, et al.
British Journal of Cancer|February 22, 2023
'Potentially curative therapies' for hepatocellular carcinoma: how many patients can actually be cured?Alessandro Cucchetti, Omar Elshaarawy, Guohong Han, et al.
Hepatology (Baltimore, Md.)|February 14, 2015
The role of hepatic resection in the treatment of hepatocellular cancerSasan Roayaie, Ghalib Jibara, Parissa Tabrizian, et al.
The American Journal of Gastroenterology|December 9, 2021
Correction to: Anticoagulation and Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis: A Prospective Observational StudyYong Lv, Wei Bai, Kai Li, et al.
The American Journal of Gastroenterology|February 25, 2021
Anticoagulation and Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis: A Prospective Observational StudyYong Lv, Wei Bai, Kai Li, et al.
Pageof 20

Showing results (141-150 of 200) with videos related to

Sort By:
Pageof 20
BMC Cancer|December 24, 2017
Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II studyRuihua Xu, Xianjun Yu, Jihui Hao, et al.
BMJ Open|July 13, 2013
Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trialXingshun Qi, Chuangye He, Zhanxin Yin, et al.
Scientific Reports|February 3, 2016
The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial ChemoembolizationLei Liu, Yan Zhao, Jia Jia, et al.
Hepatology (Baltimore, Md.)|March 10, 2022
Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trialYong Lv, Hui Chen, Bohan Luo, et al.
The FEBS Journal|January 16, 2009
Inhibition of PI3K/Akt partially leads to the inhibition of PrP(C)-induced drug resistance in gastric cancer cellsJie Liang, Fulin Ge, Changcun Guo, et al.
The Lancet. Gastroenterology & Hepatology|May 19, 2022
Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trialYong Lv, Hui Chen, Bohan Luo, et al.
British Journal of Cancer|February 22, 2023
'Potentially curative therapies' for hepatocellular carcinoma: how many patients can actually be cured?Alessandro Cucchetti, Omar Elshaarawy, Guohong Han, et al.
Hepatology (Baltimore, Md.)|February 14, 2015
The role of hepatic resection in the treatment of hepatocellular cancerSasan Roayaie, Ghalib Jibara, Parissa Tabrizian, et al.
The American Journal of Gastroenterology|December 9, 2021
Correction to: Anticoagulation and Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis: A Prospective Observational StudyYong Lv, Wei Bai, Kai Li, et al.
The American Journal of Gastroenterology|February 25, 2021
Anticoagulation and Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis: A Prospective Observational StudyYong Lv, Wei Bai, Kai Li, et al.
Pageof 20